CoChat

Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles

Open access

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Abstract

HIV-1 infection is a manageable chronic condition, with non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs) remaining a cornerstone of antiretroviral therapy. Nevertheless, drug resistance to existing therapeutics is a serious and immediate concern. Using structure-based and scaffold-hopping approaches, we designed evolved diarylpyrimidine analogs targeting reverse transcriptase (RT), exploiting chemical space surrounding the NNRTI-binding pocket. We identified compounds 5i3 and 5e2 , with robust antiviral efficacy against wild-type HIV-1 and rilpivirine-resistant strains. Encouragingly, in vitro selection of mutant strains with 5i3 took 39 passages to select resistance, with no phenotypic cross-resistance observed with known RT drugs. Co-crystal structures of wild-type and mutant RT with 5i3 and 5e2 revealed their resilience toward resistance mutations due to enhanced conformational flexibility and positional adaptability. 5i3 exhibited good pharmacokinetic properties and favorable safety profiles, without substantial cytochrome P450 inhibition, and excellent oral bioavailability. These derivatives represent a promising scaffold for the development of anti-HIV drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.adt8916

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Rational design of DAPY-evolved derivatives as potent HIV-1 inhibitors. (A) Chemical structures of the FDA-approved NNRTIs etravirine (ETR) and rilpivirine (RPV) and the lead compounds K-5a2 and 25a. (B) Illustration of the structure-based design strategy and molecular optimization campaign of DAPY-evolved derivatives in this work.
Fig. 1. Rational design of DAPY-evolved derivatives as potent HIV-1 inhibitors. (A) Chemical structures of the FDA-approved NNRTIs etravirine (ETR) and rilpivirine (RPV) and the lead compounds K-5a2 and 25a. (B) Illustration of the structure-based design strategy and molecular optimization campaign of DAPY-evolved derivatives in this work.CC BY-NC · PubMed Central
Fig. 2. Biological activity evaluation results of the designed compounds. (A) Anti–HIV-1 (WT) activity of series 5a. (B) Anti–HIV-1 (WT) activity of series 5b–e, 5g, and 5h. (C) Anti–HIV-1 (WT) activity of series 5f and 5i. (D) Kinetics of resistance development for the HIV-1 (IIIB) following selective pressure with compounds 5e2 and 5i3. HIV-1 (IIIB) was cultured in MT-4 cells for 39 passages in the presence of increasing compound concentrations.
Fig. 2. Biological activity evaluation results of the designed compounds. (A) Anti–HIV-1 (WT) activity of series 5a. (B) Anti–HIV-1 (WT) activity of series 5b–e, 5g, and 5h. (C) Anti–HIV-1 (WT) activity of series 5f and 5i. (D) Kinetics of resistance development for the HIV-1 (IIIB) following selective pressure with compounds 5e2 and 5i3. HIV-1 (IIIB) was cultured in MT-4 cells for 39 passages in the presence of increasing compound concentrations.CC BY-NC · PubMed Central
Fig. 3. Polder OMIT maps for each ligand in either the WT RT or GH9 RT complexes. (A) Polder OMIT maps for WT RT/5i3 (1.99-Å resolution) and WT RT/5e2 (2.18-Å resolution). (B) Polder OMIT maps for GH9 RT/5i3 (2.36-Å resolution) and GH9 RT/5e2 (2.15-Å resolution). All maps are shown at a contour of 3.0σ.
Fig. 3. Polder OMIT maps for each ligand in either the WT RT or GH9 RT complexes. (A) Polder OMIT maps for WT RT/5i3 (1.99-Å resolution) and WT RT/5e2 (2.18-Å resolution). (B) Polder OMIT maps for GH9 RT/5i3 (2.36-Å resolution) and GH9 RT/5e2 (2.15-Å resolution). All maps are shown at a contour of 3.0σ.CC BY-NC · PubMed Central
Fig. 4. Interactions of WT RT and GH9 RT with bound inhibitors. (A) Co-crystal structures of 5i3 (yellow ball and stick) and WT RT (green sticks). (B) Co-crystal structures of 5e2 (violet ball and stick) and WT RT (green sticks). (C) Co-crystal structures of 5i3 (yellow ball and stick) and GH9 RT (red sticks). (D) Co-crystal structures of 5e2 (violet ball and stick) and GH9 RT (red sticks). Hydrogen bonds are indicated by blue lines and waters are shown as red spheres.
Fig. 4. Interactions of WT RT and GH9 RT with bound inhibitors. (A) Co-crystal structures of 5i3 (yellow ball and stick) and WT RT (green sticks). (B) Co-crystal structures of 5e2 (violet ball and stick) and WT RT (green sticks). (C) Co-crystal structures of 5i3 (yellow ball and stick) and GH9 RT (red sticks). (D) Co-crystal structures of 5e2 (violet ball and stick) and GH9 RT (red sticks). Hydrogen bonds are indicated by blue lines and waters are shown as red spheres.CC BY-NC · PubMed Central
Fig. 5. Superposition of WT and K101P/K103N/V108I (GH9) RT complexes illustrate rearrangements of the NNIBP to overcome resistance mutations. (A) WT RT bound to 5e2 (pale green) superposed onto GH9 RT bound to 5e2 (violet). (B) WT RT bound to 5i3 (pale green) superposed onto GH9 RT bound to 5i3 (pale yellow). Zoomed-in regions are shown at the bottom of the image. Hydrogen bonds are shown as blue sticks, and hydrophobic interactions are shown as yellow dashes.
Fig. 5. Superposition of WT and K101P/K103N/V108I (GH9) RT complexes illustrate rearrangements of the NNIBP to overcome resistance mutations. (A) WT RT bound to 5e2 (pale green) superposed onto GH9 RT bound to 5e2 (violet). (B) WT RT bound to 5i3 (pale green) superposed onto GH9 RT bound to 5i3 (pale yellow). Zoomed-in regions are shown at the bottom of the image. Hydrogen bonds are shown as blue sticks, and hydrophobic interactions are shown as yellow dashes.CC BY-NC · PubMed Central
Fig. 6. Preliminary drug-like profiles evaluation of compound 5i3. (A) Inhibitory activity of compound 5i3 against the hERG potassium channel in the CHO-hERG cell. (B) Body weights of all Kunming mice in the 5i3 administration group and the vehicle control group during the acute toxicity assay. (C) Plasma concentration–time curve of 5i3 following oral administration (20 mg/kg po) and intravenous administration (2 mg/kg iv) in Sprague-Dawley rats.
Fig. 6. Preliminary drug-like profiles evaluation of compound 5i3. (A) Inhibitory activity of compound 5i3 against the hERG potassium channel in the CHO-hERG cell. (B) Body weights of all Kunming mice in the 5i3 administration group and the vehicle control group during the acute toxicity assay. (C) Plasma concentration–time curve of 5i3 following oral administration (20 mg/kg po) and intravenous administration (2 mg/kg iv) in Sprague-Dawley rats.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Cited by

See all 7

Metadata

Authors
Wang, Z., Rumrill, S., Kang, D., Guma, S. D., Feng, D., De Clercq, E., Pannecouque, C., Chen, C. H., Arnold, E., Ruiz, F. X., Liu, X., & Zhan, P.
Affiliations
  • Shandong University (CN)
  • Rutgers, The State University of New Jersey (US)
  • Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, K.U. Leuven, Herestraat 49 Postbus 1043 (09.A097), B-3000 Leuven, Belgium.
  • Rega Institute for Medical Research (BE)
  • Duke Medical Center (US)
Corresponding author
  • Wang, Zhao
  • Rumrill, Shawn
  • Kang, Dongwei
  • Guma, Samuel Desta
  • Chen, Chin Ho
  • Arnold, Eddy
  • Ruiz, Francesc Xavier
  • Liu, Xinyong
  • Zhan, Peng
Venue
Science Advances
Published
2025-05-30
Volume
11
Issue
22
Pages
eadt8916-eadt8916
ISSN
2375-2548 (ISSN-L)
OpenAlex
W4410886466
Cited by
7
References
74
Citations by year
2026: 6 · 2025: 1
FWCI
5.39
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion, cc-by-nc)
Funders
  • Shandong University (SYS202205)
  • Ministry of Science and Technology of the People's Republic of China (2019ZX09301-126)
  • Natural Science Foundation of Shandong Province (ZR2020JQ31, ZR2020YQ61)
  • National Institutes of Health
  • National Institute of General Medical Sciences (GM135141, GM008339, T32GM008339)
  • National Institute of Allergy and Infectious Diseases (R01AI027690)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords
HIV-1, non-nucleoside reverse transcriptase inhibitors, drug resistance, reverse transcriptase, structure-based drug design, scaffold hopping, antiviral efficacy, pharmacokinetics, oral bioavailability, cytochrome P450 inhibition, co-crystal structure, conformational flexibility
MeSH terms
Rilpivirine, Animals, Humans, Microbial Sensitivity Tests, Mutation, Structure-Activity Relationship, HIV-1, HIV Infections, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Drug Resistance, Viral, HIV Reverse Transcriptase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.